Skip to content

BlossomHill Therapeutics

US · BLSM #3711 by market cap Listed 2026
14.51 +0.10 +0.69%
Periodic snapshot; not a real-time feed. · 2026-11-20 16:10

Price chart

Pre-market 14.31 -0.70%
After-hours 14.51 0.00%
26.8212.3514.512026-08-072026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on BLSM?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -8.2% on average (3-month/1-year).
  • Main-fund capital flow has been a net inflow over the last 45 sessions.
  • Short interest has risen to 1.9% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Neutral
  • Price is above its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days C → C

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Performance

1W +3.50%
1M +0.76%
3M -8.16%

Key statistics

Price & volume

Prev close
14.41
Open
14.34
Day range
13.90 - 15.63
Avg price
14.44
Volume
270.74K
Turnover
3.91M
Amplitude
12.01%
52-week range
11.02 - 27.99

Valuation

P/E
-3.93
P/E (TTM)
-5.11
P/B
2.18
EPS
-3.69
Net profit
-117.29M
Net assets
211.08M

Share structure

Market cap
461.20M
Float cap
136.03M
Shares out
31.78M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2026-08-07
52-week range 21% of range
11.02 27.99

48.2% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

+362.96K net over the window

Short interest

Shares short
590.13K
As of
2026-10-30

Frequently asked questions

What is the current stock price of BlossomHill Therapeutics (BLSM)?

BlossomHill Therapeutics last traded at 14.51. This page shows a periodic quote snapshot. Check the displayed quote time.

What is BlossomHill Therapeutics's market cap?

About 461.20M.

What is the P/E ratio of BlossomHill Therapeutics?

The trailing twelve-month P/E is -5.11. The Valuation tab shows it against the stock's own five-year range.

Does BlossomHill Therapeutics pay a dividend?

BlossomHill Therapeutics does not currently pay a regular dividend.

Is BlossomHill Therapeutics a buy according to analysts?

The consensus of 5 analysts is a Buy rating, with an average 12-month price target of 36.75, which implies 153.3% upside from the current price. This is not investment advice.

What is BlossomHill Therapeutics's StockVane Quant Rating?

The StockVane Momentum strategy currently rates BlossomHill Therapeutics a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.

Quote time 2026-11-20 16:10:04 · For reference only, not investment advice and not tailored to your situation.

BlossomHill Therapeutics discussion 0 comments

Add a comment